Targeting myosin 1c inhibits murine hepatic fibrogenesis-Reference-Cited by-同舟云学术

Targeting myosin 1c inhibits murine hepatic fibrogenesis

Published:2021-06-01 Issue:6 Volume:320 Page:G1044-G1053
ISSN:0193-1857
Container-title:American Journal of Physiology-Gastrointestinal and Liver Physiology
language:en
Short-container-title:American Journal of Physiology-Gastrointestinal and Liver Physiology

Author:

Arif Ehtesham¹²^ORCID,Wang Cindy²,Swiderska-Syn Marzena K.³,Solanki Ashish K.¹,Rahman Bushra¹,Manka Paul P.²⁴,Coombes Jason D.⁵⁶,Canbay Ali⁴,Papa Salvatore⁷,Nihalani Deepak¹⁸,Aspichueta Patricia⁹,Lipschutz Joshua H.¹¹⁰,Syn Wing-Kin²⁹¹¹

Affiliation:

1. Department of Medicine, Nephrology Division, Medical University of South Carolina, Charleston, South Carolina

2. Division of Gastroenterology and Hepatology, Medical University of South Carolina, Charleston, South Carolina

3. Department of Pediatrics, Darby Children’s Research Institute, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina

4. Department of Medicine, University Hospital Knappschaftskrankenhaus, Ruhr-University Bochum, Bochum, Germany

5. Institute of Hepatology, Foundation for Liver Research, London, United Kingdom

6. School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom

7. Leeds Institute of Medical Research at St. James’s, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom

8. Division of Kidney, Urologic and Hematologic Diseases, National Institutes of Health, Bethesda, Maryland

9. Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country, Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), Leioa, Spain

10. Section of Nephrology, Ralph H Johnson Veterans Affairs Medical Center, Charleston, South Carolina

11. Section of Gastroenterology, Ralph H Johnson Veterans Affairs Medical Center, Charleston, South Carolina

Abstract

The incidences of liver fibrosis are growing at a rapid pace and have become one of the leading causes of end-stage liver disease. Although TGF-β1 is known to play a prominent role in transforming cells to produce excessive extracellular matrix that lead to hepatic fibrosis, the therapies targeting TGF-β1 have achieved very limited clinical impact. This study highlights motor protein myosin-1c-mediated mechanisms that serve as novel regulators of TGF-β1 signaling and fibrosis

Funder

HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases

U.S. Department of Veterans Affairs

Publisher

American Physiological Society

Subject

Physiology (medical),Gastroenterology,Hepatology,Physiology

Link

https://journals.physiology.org/doi/pdf/10.1152/ajpgi.00105.2021

Reference46 articles.

1. Treatment with 4-Methylpyrazole Modulated Stellate Cells and Natural Killer Cells and Ameliorated Liver Fibrosis in Mice

2. Liver regeneration and fibrosis after inflammation